Cellectar Biosciences Inc Market Cap ($5.17 Million)
Market Cap & Net Worth: Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc market cap. Cellectar Biosciences Inc (NASDAQ:CLRB) has a market capitalization of $5.17 Million ($5.17 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28451 globally and #5855 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellectar Biosciences Inc's stock price $1.22 by its total outstanding shares 4240129 (4.24 Million). Also see Cellectar Biosciences Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Cellectar Biosciences Inc Market Cap History (2015–2026)
Cellectar Biosciences Inc market cap history from 2015 to 2026. Data shows change from $3.12 Billion to $5.17 Million (-48.81% CAGR). Check CLRB live share price for real-time trading data and today's change.
Index Memberships
Cellectar Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #813 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2609 of 3165 |
Weight: Cellectar Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellectar Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellectar Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CLRB net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CLRB by Market Capitalization
Companies near Cellectar Biosciences Inc in the global market cap rankings as of November 3, 2026. Also see Cellectar Biosciences Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Cellectar Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Cellectar Biosciences Inc (2015–2026)
Market capitalization of Cellectar Biosciences Inc from 2015 to today. Between 2015 and today, Cellectar Biosciences Inc's market cap moved from $3.12 Billion to $ 5.17 Million, with a yearly change of -48.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.17 Million | -58.64% |
| 2025 | $12.51 Million | +886.62% |
| 2024 | $1.27 Million | -89.21% |
| 2023 | $11.75 Million | +61.99% |
| 2022 | $7.25 Million | -74.25% |
| 2021 | $28.15 Million | -68.08% |
| 2020 | $88.19 Million | -7.56% |
| 2019 | $95.40 Million | +45.16% |
| 2018 | $65.72 Million | -88.69% |
| 2017 | $580.90 Million | +12.30% |
| 2016 | $517.30 Million | -83.40% |
| 2015 | $3.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Cellectar Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.17 Million USD |
| MoneyControl | $5.17 Million USD |
| MarketWatch | $5.17 Million USD |
| marketcap.company | $5.17 Million USD |
| Reuters | $5.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more